- Home
- LXEO vs MIST Comparison
LXEO vs MIST Comparison
Compare LXEO & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEO
- MIST
- Stock Information
- Founded
- LXEO 2017
- MIST 2003
- Country
- LXEO United States
- MIST Canada
- Employees
- LXEO N/A
- MIST N/A
- Industry
- LXEO
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- LXEO
- MIST Health Care
- Exchange
- LXEO Nasdaq
- MIST Nasdaq
- Market Cap
- LXEO 93.9M
- MIST 132.5M
- IPO Year
- LXEO 2023
- MIST N/A
- Fundamental
- Price
- LXEO $4.65
- MIST $1.45
- Analyst Decision
- LXEO Strong Buy
- MIST Strong Buy
- Analyst Count
- LXEO 5
- MIST 2
- Target Price
- LXEO $16.60
- MIST $7.50
- AVG Volume (30 Days)
- LXEO 435.8K
- MIST 2.8M
- Earning Date
- LXEO 08-11-2025
- MIST 08-07-2025
- Dividend Yield
- LXEO N/A
- MIST N/A
- EPS Growth
- LXEO N/A
- MIST N/A
- EPS
- LXEO N/A
- MIST N/A
- Revenue
- LXEO N/A
- MIST N/A
- Revenue This Year
- LXEO N/A
- MIST N/A
- Revenue Next Year
- LXEO N/A
- MIST N/A
- P/E Ratio
- LXEO N/A
- MIST N/A
- Revenue Growth
- LXEO N/A
- MIST N/A
- 52 Week Low
- LXEO $1.45
- MIST $0.63
- 52 Week High
- LXEO $13.63
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- LXEO 61.04
- MIST 41.23
- Support Level
- LXEO $3.60
- MIST $1.48
- Resistance Level
- LXEO $4.31
- MIST $1.64
- Average True Range (ATR)
- LXEO 0.33
- MIST 0.15
- MACD
- LXEO -0.00
- MIST -0.04
- Stochastic Oscillator
- LXEO 71.95
- MIST 15.52
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).